

Appl. No. 10/019,832  
Amdt. dated January 28, 2004  
Reply to Office Action of October 31, 2003

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1. (currently amended) An isolated nucleic acid molecule comprising consisting of nucleotides 36-1171 of the nucleotide sequence of SEQ ID NO: 1 or a fragment of at least 15 nucleotides thereof.

Claim 2. (cancel)

Claim 3. (cancel)

Claim 4. (currently amended) A method for detecting the a nucleic acid molecule of claim 1 comprising nucleotides 36-1171 of SEQ ID NO:1, comprising:

(a) a step of

(i) hybridizing a probe comprising at least 15 nucleotides of nucleotides 36-1171 of SEQ ID NO:1 to a nucleic acid molecule to be detected; or

(ii) amplifying a nucleic acid molecule to be detected using a primer comprising at least 15 nucleotides of nucleotides 36-1171 of SEQ ID NO:1, and

(b) detecting the hybridization or amplification, wherein said method uses DNA that hybridizes to SEQ ID NO:1.

Claim 5. (currently amended) A method for testing for an allergic disease a cedar pollen allergy, said method comprising the steps of:

(a) preparing T cells from a subject,

(b) preparing an RNA sample from said T cells,

(c) conducting hybridization with said RNA sample using the DNA of claim 3 a nucleic acid that specifically hybridizes to nucleotides 36-1171 of SEQ ID NO:1 as a probe,

wherein said ~~DNA~~ probe is labeled, and

(d) measuring the amount of RNA that is derived from said subject and that hybridizes with said ~~DNA~~ probe and comparing said amount with the amount of RNA of a control (normal group) group which has a normal level of cedar pollen specific IgE, wherein if the amount of gene 513 RNA is significantly higher in a sample from the subject than in the control group, then the subject is determined to have a cedar pollen allergy.

Claim 6. (currently amended) A method for testing for ~~an allergic disease~~ a cedar pollen allergy, said method comprising the steps of:

(a) preparing T cells from a subject,  
(b) preparing an RNA sample from said T cells,  
(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,  
(d) conducting polymerase chain reaction (PCR) using said cDNA as template and ~~the DNA of claim 3~~ a primer that specifically hybridizes to nucleotides 36-1171 of SEQ ID NO:1 as primer, and

(e) comparing the amount of a DNA amplified by said PCR with a control ~~(normal group)~~ group which has a normal level of cedar pollen specific IgE, wherein if the amount of gene 513 cDNA is significantly higher in a sample from the subject than in the control group, then the subject is determined to have a cedar pollen allergy.

Claim 7. (original) The method of claim 6, wherein said PCR is carried out by a PCR amplification monitoring method.

Claim 8. (previously presented) The method of claim 5, wherein said T cells are prepared from peripheral blood of said subject.

Claim 9. (cancel)

Claim 10. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,
- (b) preparing T cells from said model animal,
- (c) preparing an RNA sample from said T cells,
- (d) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,
- (e) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and
- (f) selecting a compound that reduces the amount of said RNA measured in (e), compared to a control (a case where said test compound is not administered).

Claim 11. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,
- (b) preparing T cells from said model animal,
- (c) preparing an RNA sample from said T cells,
- (d) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
- (e) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
- (f) selecting a compound that reduces the amount of said DNA amplified in (e), compared to a control (a case where said test compound is not administered).

Claim 12. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal,

- (b) preparing lymphocytes from said model animal,
- (c) stimulating said lymphocytes with pollen antigen,
- (d) separating T cells from said lymphocytes stimulated with said antigen,
- (e) preparing an RNA sample from said T cells,
- (f) conducting hybridization with said RNA sample using the DNA that hybridizes to SEQ ID NO:1 as probe, wherein said DNA is labeled,
- (g) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and
- (h) selecting a compound that reduces the amount of said RNA measured in (g), compared to a control (a case where said test compound is not administered).

Claim 13. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal,
- (b) preparing lymphocytes from said model animal,
- (c) stimulating said lymphocytes with pollen antigen;
- (d) separating T cells from said lymphocytes stimulated with said antigen,
- (e) preparing an RNA sample from said T cells,
- (f) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
- (g) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
- (h) selecting a compound that reduces the amount of said DNA amplified in (g), compared to a control (a case where said test compound is not administered).

Claim 14. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

- (b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,
- (c) separating T cells from said lymphocytes stimulated with said antigen,
- (d) preparing an RNA sample from said T cells,
- (e) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,
- (f) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and
- (g) selecting a compound that reduces the amount of said RNA measured in (f), compared to a control (a case where said test compound is not administered).

Claim 15. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,
- (b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,
- (c) separating T cells from said lymphocytes stimulated with said antigen,
- (d) preparing an RNA sample from said T cells,
- (e) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
- (f) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
- (g) selecting a compound that reduces the amount of said DNA amplified in (f), compared to a control (a case where said test compound is not administered).

Claim 16. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) stimulating a T-cell line with a lymphocyte-stimulating substance in the

presence of a test compound,

(b) preparing an RNA sample from said stimulated T-cell line,

(c) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(d) measuring the amount of RNA that is derived from said T-cell line and that hybridizes with said DNA, and

(e) selecting a compound that reduces the amount of said RNA measured in (d), compared to a control (a case where said test compound is not administered).

Claim 17. (withdrawn) A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

(b) preparing an RNA sample from said stimulated T-cell line,

(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(e) selecting a compound that reduces the amount of said DNA amplified in (d), compared to a control (a case where said test compound is not administered).

Claim 18. (withdrawn) The method of claim 10, wherein said T cells are prepared from peripheral blood of said pollen allergy model animal.

Claim 19. (withdrawn) The method of claim 12, wherein said lymphocytes are prepared from peripheral blood.

Appl. No. 10/019,832

PATENT

Amdt. dated January 28, 2004

Reply to Office Action of October 31, 2003

Claim 20. (withdrawn) The method of claim 10, wherein said allergic disease is a cedar pollen allergy.